Pradip Nair

This inventor holds 11 USPTO granted patents and 9 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Biocon Limited, Centro De Inmunologia Molecular, Biocon Limited & Centro De Immunologia Molecular. Active years: 2013-2024.

USPTO Granted Patents = 11 (Patent Applications = 9)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 7.6

ph-index = 4

Forward Citations = 35(Granted Patents)

Location History:

Karnataka, IN (2013 - 2018)
Bengaluru, IN (2018 - 2024)

Company Filing History:

Centro De Inmunologia Molecular

patents

1 out of 1

Biocon Limited & Centro De Immunologia Molecular

patent

4. 1 out of 8

Centro De Immunologia Molecular

patents

5. 1 out of 1

Centro De Inmunolgia Molecular

patent

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11981743 - Monoclonal antibody and a method thereof (2024-05-14),

2. 11242401 - Monoclonal antibody and a method of use for the treatment of lupus (2022-02-08),

3. 11028168 - Use of a CD6 binding partner and method based thereon (2021-06-08),

4. 10669346 - Monoclonal antibody and a method thereof (2020-06-02),

5. 10308970 - Methods for controlling fucosylation levels in proteins (2019-06-04),

6. 10189899 - Use of a CD6 binding partner and method based thereon (2019-01-29),

7. 10000573 - Monoclonal antibody and a method thereof (2018-06-19),

8. 9856502 - Methods for controlling fucosylation levels in proteins (2018-01-02),

9. 9670285 - Monoclonal antibody and a method thereof (2017-06-06),

10. 9217037 - Monoclonal antibody and a method thereof (2015-12-22),

11. 8524233 - Monoclonal antibody and a method thereof (2013-09-03),

Title: The Innovations of Pradip Nair

Introduction

Pradip Nair, a prolific inventor based in Bengaluru, India, has made significant contributions to the field of biomedicine. With a remarkable portfolio of 11 patents, he has established himself as a prominent figure in the development of therapeutic antibodies and novel treatment methodologies.

Latest Patents

Among his most notable recent inventions is a monoclonal antibody and a method thereof, specifically a humanized IgG1 isotype anti-CD6 antibody (T1h). This antibody binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6, which is present on the surface of various immune cells, including thymic epithelial cells, monocytes, and activated T cells. Additionally, he has developed a monoclonal antibody and a method of use for the treatment of lupus. This invention relates to compositions and methods that utilize the humanized IgG1 anti-CD6 monoclonal antibody (T1h), specifically designed to bind to the SRCR domain 1 (D1) of CD6 without interfering with its interaction with the CD6 ligand, Activated Leukocyte Cell Adhesion Molecule (ALCAM).

Career Highlights

Throughout his career, Pradip Nair has worked with esteemed organizations such as Biocon Limited and Centro De Inmunologia Molecular. His experience in these companies has enabled him to harness innovative approaches to antibody development and therapeutic interventions.

Collaborations

Pradip has collaborated with notable professionals in his field, including Ramakrishnan Melarkode and Jose Enrique Montero Casimiro. These partnerships have been instrumental in advancing his research and contributing to the successful development of his patents.

Conclusion

Pradip Nair’s work exemplifies the spirit of innovation in the biomedical sector. His contributions, notably in monoclonal antibody development for therapeutic purposes, represent important advancements in the treatment of autoimmune disorders such as lupus. Through his continued efforts and collaborations, he has positioned himself as a key innovator in his field.